Viridian Therapeutics, Inc. entered into an underwriting agreement for the sale of its common stock, raising approximately $150.0 million, and expects to have enough funds to operate until the second half of 2026. Preliminary financial information shows the company had $477.4 million in cash, cash equivalents, and short-term investments as of December 31, 2023.